- Home
- PSF vs SERA Comparison
PSF vs SERA Comparison
Compare PSF & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PSF | SERA |
|---|---|---|
| Founded | 2010 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 251.0M | 130.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | PSF | SERA |
|---|---|---|
| Price | $20.38 | $3.25 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 25.0K | ★ 63.8K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 7.69% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $95,000.00 |
| Revenue This Year | N/A | $25.84 |
| Revenue Next Year | N/A | $347.37 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1.06 |
| 52 Week Low | $16.00 | $1.37 |
| 52 Week High | $20.19 | $8.73 |
Technical Indicators
Market Signals| Indicator | PSF | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 54.93 | 47.49 |
| Support Level | $20.22 | $2.80 |
| Resistance Level | $20.39 | $3.18 |
| Average True Range (ATR) | 0.11 | 0.24 |
| MACD | 0.03 | -0.05 |
| Stochastic Oscillator | 98.03 | 40.00 |
Price Performance
Historical ComparisonAbout PSF Cohen & Steers Select Preferred and Income Fund Inc.
Cohen & Steers Select Preferred and Income Fund Inc is a diversified, closed-end investment company. The Fund's primary investment objective is high current income with capital appreciation as its secondary objective. The Fund invests at least of its Managed Assets in preferred and other income securities issued by U.S. and non-U.S. companies.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.